Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYC-30937-EC induction therapy in active ulcerative colitis
2016-000518-31Phase 2Completed
- Sponsor
- Lycera
- Start
- Jun 2016
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing LYC-30937-EC with Placebo (2 arms). Primary endpoint: Clinical remission at Week 8 by modified Mayo score. Started Jun 2016; status: completed.
02
Drugs
parimifasor
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-000518-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000518-31.